论文部分内容阅读
目的 :探讨血管紧张素转换酶抑制剂 (ACEI)联用血管紧张素Ⅱ -1型受体 (AT1 )拮抗剂治疗早期糖尿病肾病的合理性。方法 :76例 2型糖尿病肾病患者随机分为 3组 ,分别使用苯那普利 (n =2 5 )、氯沙坦 (n =2 7)及两药合用 (n =2 4)治疗 6周 ,治疗前后分别测 2 4hUAE、血清尿素 (BUN )、血清肌酐 (Cr) ,进行同期组间比较及组内治疗后比较。结果 :3组治疗后 2 4hUAE、Cr、BUN浓度均显著低于治疗前 ;苯那普利组与氯沙坦组比较疗效差异无统计学意义 ,而联用组疗效明显优于苯那普利组及氯沙坦组。结论 :ACEI与AT1 拮抗剂联合应用治疗糖尿病肾病是合理的、安全的
Objective: To investigate the rationality of angiotensin converting enzyme inhibitor (ACEI) combined with angiotensin Ⅱ type 1 receptor (AT1) antagonist in the treatment of early diabetic nephropathy. Methods: A total of 76 patients with type 2 diabetic nephropathy were randomly divided into 3 groups: benazepril (n = 25), losartan (n = 27) and combination of both drugs , 24 hours UAE, BUN and Cr were measured before and after treatment. Results: The levels of UAE, Cr and BUN in 3 groups after treatment were significantly lower than those before treatment. There was no significant difference in efficacy between benazepril group and losartan group, but the combination group was better than benazepril Group and losartan group. Conclusion: It is reasonable and safe to treat diabetic nephropathy with ACEI and AT1 antagonist